Vermillion this week released data from a new prospective, multi-center clinical study on its ovarian cancer diagnostic OVA1 that the company said "confirms and extends" previous studies supporting use of the test.

The 494-patient study, called OVA500, was conducted by Robert Bristow, director of gynecological oncology services at University of California, Irvine, Healthcare, and found that OVA1 identified ovarian cancer in women with an adnexal mass with sensitivity of 96 percent and specificity of 51 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.